Great Diamond Partners LLC Lowers Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Great Diamond Partners LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 0.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 30,104 shares of the company’s stock after selling 157 shares during the period. Great Diamond Partners LLC’s holdings in Novo Nordisk A/S were worth $2,590,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Raymond James & Associates grew its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC increased its stake in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the last quarter. LPL Financial LLC lifted its stake in shares of Novo Nordisk A/S by 3.6% in the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after buying an additional 47,496 shares in the last quarter. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $98,765,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.2 %

Shares of NYSE:NVO opened at $84.36 on Friday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The stock has a market capitalization of $378.56 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock’s 50-day simple moving average is $93.97 and its two-hundred day simple moving average is $113.62.

Analyst Ratings Changes

Several research firms recently issued reports on NVO. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.